---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-021986"
form_type: "8-K"
ticker: "PTGX"
cik: "0001377121"
company_name: "Protagonist Therapeutics, Inc"
filed_at: "2025-03-10T23:59:59+00:00"
generated_at: "2026-05-25T00:59:18.403419+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 1.0
calibrated_materiality_score: 1.0
confidence: "high"
source: SEC EDGAR
---

# Icotrokinra Phase 3 PsO hits 46% complete skin clearance; UC Phase 2b meets endpoint

## Summary
- Phase 3 ICONIC-LEAD: 46% of icotrokinra patients achieved IGA 0 (completely clear skin) at Week 24; 74% IGA 0/1.
- ICONIC-ADVANCE 1&2 met co-primary endpoints and showed superiority over deucravacitinib at Weeks 16 and 24; head-to-head vs ustekinumab (ICONIC-ASCEND) initiated.
- Phase 2b ANTHEM-UC: 63.5% clinical response at highest dose at Week 12 vs 27.0% placebo (p<0.001); 30.2% clinical remission vs 11.1% (p<0.001).
- Both studies show favorable safety; AEs similar to placebo. Icotrokinra is a first-in-class oral IL-23 receptor antagonist.
- Results support potential paradigm shift in plaque psoriasis and ulcerative colitis; partner J&J advancing program.

## SEC filing metadata
- accession: 0001104659-25-021986
- form_type: 8-K
- ticker: PTGX
- cik: 0001377121
- company_name: Protagonist Therapeutics, Inc
- filed_at: 2025-03-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 1.0
- calibrated_materiality_score: 1.0
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1377121/000110465925021986/0001104659-25-021986-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1377121/000110465925021986/tm258665d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-021986
- JSON: https://secwatch.observer/filing/0001104659-25-021986.json
- Plain text: https://secwatch.observer/filing/0001104659-25-021986.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.